Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China

  • Yuelu Zhu1,
  • Yongkun Sun2,
  • Shangying Hu3,
  • Yong Jiang3,
  • Jiangying Yue1, 4,
  • Xuemin Xue1,
  • Lin Yang2 and
  • Liyan Xue1Email author
BMC GastroenterologyBMC series – open, inclusive and trusted201717:41

DOI: 10.1186/s12876-017-0598-5

Received: 30 August 2016

Accepted: 8 March 2017

Published: 14 March 2017

Abstract

Background

Neoadjuvant chemotherapy has been increasingly practiced on gastric cancer (GC), and histological evaluation to predict outcome is urgent in clinical practice. There are five classic tumor regression grading (TRG) systems, including Mandard-TRG system, the Japanese Gastric Cancer Association (JGCA)-TRG system, College of American Pathologists (CAP)-TRG system, China-TRG system and Becker-TRG system.

Methods

Totally, 192 patients of gastric adenocarcinoma (including adenocarcinoma of the esophagogastric junction) treated by neoadjuvant chemotherapy and surgery were evaluated using the above five TRG systems. The clinicopathological characteristics were also assessed. The correlation among TRG systems, clinicopathological characteristics and prognosis were analyzed.

Results

All the five TRG systems were significantly correlated with differentiation, postsurgical T category, postsurgical N category, American Joint Committee on Cancer (AJCC) stage, lymph-vascular invasion, perineural invasion, as well as tumor size. All the five TRG systems were statistically significant in univariate Cox survival analysis. However, only postsurgical T category, postsurgical N category and R0 resection were independent in multivariate Cox survival analysis. The tight correlation between the TRG systems and other characteristics such as postsurgical stage might affect the independent prognostic role of the TRG systems. As compared with other TRG systems, the hazard ratio of no/slightly response in both Mandard TRG system and JGCA TRG system revealed higher hazard of death and disease progression than that of severe response when using univariate Cox survival analysis. The median survival time of complete response and nearly complete response were much longer than that of partial response, all classified by Mandard-TRG system. This could help clinicians predict prognosis more reasonably than JGCA-TRG which does not have the category of nearly complete response.

Conclusion

We recommend Mandard-TRG system for GC after neoadjuvant chemotherapy due to its better prediction of prognosis.

Keywords

Gastric cancer Neoadjuvant chemotherapy Tumor regression grading

Background

In 2012, 951,000 new diagnoses of gastric cancer (GC) and 723,000 GC deaths were calculated worldwide, accounting for 6.8% of all cancer incidence and 8.8% of all cancer mortality, respectively [1]. At present, GC is the second common cancer in China, while approximately 679,100 new cancer cases and 498,000 related deaths were estimated in China in 2015 [2]. The most promising curative treatment for GC is surgical resection. However, this treatment alone is not enough for curing advanced GC because of poor long-term outcome, thus a multimodality therapy is required. Nowadays, neoadjuvant chemotherapy has been increasingly used to prolong patient survival worldwide [3], therefore an effective histopathological evaluation method predicting patient prognosis is urgently needed in clinical practice. So far, four tumor regression grading (TRG) systems were presented by several studies. Mandard et al. proposed a five-tiered TRG system in esophageal carcinoma which has been used widely in digestive malignancy [4]. The Japanese Gastric Cancer Association (JGCA) suggested a different five-tiered grading system specifically for GC [5]. College of American Pathologists (CAP) recommended a simplified four-tiered grading system based on Mandard-TRG system [6]. In China, a three-tiered grading system has been used for solid malignancies to evaluate the extent of therapy-related tumor regression [7]. In recent years, Becker et al. recommended a four-tiered grading system for GC based on large number of patients and long-term follow-up [8, 9]. For the purpose of further evaluation of the relationship between TRG and prognosis, we retrospectively collected 192 patients in our hospital. We used the above five TRG systems to assess the pathological response respectively, trying to select a better histopathological evaluation system.

Methods

Patients

Between January 2007 and August 2013, 192 patients with locally advanced gastric adenocarcinoma (including adenocarcinoma of the esophagogastric junction) underwent gastrectomy in National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. All the patients received neoadjuvant chemotherapy previously. The treatment strategies were not uniform, and the drugs most used included oxaliplatin, cisplatin, docetaxel, 5-fluorouracil and Tegafur Gimeracil Oteracil Potassium Capsule. There were 133 patients who received additional adjuvant chemotherapy after surgery. All cases had only one primary gastric tumor, except one patient, who had two primary lesions located at the fundus and antrum, separately. The tumor located at the fundus was evaluated in our study for its relatively higher T category. There were 139 male and 53 female, and the age ranged 31–77 years old (median age, 55 years old).

Follow-up

The mortality data was mainly gathered from clinical archives, or via telephone and mail. After treatment, patients were evaluated every 3 months for the first 2 years, and subsequently every 6 months for the following 3 years, and then annually according to institutional policy. Information of recurrence was updated every time the patients came for follow-up visits. The time of overall-survival (OS) was calculated from the first day of the neoadjuvant chemotherapy to the day when death occurred or to the last follow-up (September 2015). The time of progression-free-survival (PFS) was calculated from the first day of the neoadjuvant chemotherapy to the day when progression happened, death occurred or to the last follow-up (September 2015). Eleven patients were lost to follow-up. The median follow-up time was 31 months (4.1–95.3 months). Three patients, who died as the result of surgery complications, and 8 patients, whose follow-up time after surgery were less than 3 months, were excluded from the survival analysis.

Assessment of the specimens

If obvious residual carcinoma was identified macroscopically, the tumor specimen was sampled for at least 1 block per centimeter. If the maximum of residue was less than 3 cm or only areas of scar existed, the whole suspected lesion was submitted completely for histological examination. Four-micrometer sections were stained with hematoxylin and eosin. The average of slides per residual tumor was 9.7 (3–77), while the median number of the examined lymph nodes per case was 24 (3–58).

Clinicopathological characteristics

The clinicopathological features include tumor location, tumor size, histological differentiation, Laurén classification, lymph-vascular invasion (LVI) and perineural invasion (PNI). The tumor staging was based on the American Joint Committee on Cancer (AJCC) cancer staging 7th edition [10]. All the slides were reviewed by three experienced pathologists (YZ, JY and LX). In case of a disagreement about diagnosis, three pathologists reviewed the slides on a multi-headed microscope and reached a consensus diagnosis.

Tumor regression grading systems

The criteria of the five TRG systems are shown in Table 1.
Table 1

Criteria of five tumor regression grading systems

TRG system

Grade

Description

Mandard-TRG

1

No residual cancer

2

Rare residual cancer cells

3

Fibrosis outgrowing residual cancer

4

Residual cancer outgrowing fibrosis

5

Absence of regressive changes

JGCA-TRG

0

No evidence of effect

1a

Viable tumor cells occupy more than 2/3 of the tumorous area

1b

Viable tumor cells remain in more than 1/3 but less than 2/3 of the tumorous area

2

Viable tumor cells remain in less than 1/3 of the tumorous area

3

No viable tumor cells remain

CAP-TRG

0

No viable cancer cells (complete response)

1

Single cells or small groups of cancer cells (moderate response)

2

Residual cancer outgrown by fibrosis (minimal response)

3

Minimal or no tumor killed or extensive residual cancer (poor response)

China-TRG

Severe response

Tumor cells completely disappear or very few highly regressive residue exist with obvious scarring and varying inflammation

Moderate response

Most tumor cells degenerate and necrosis with obvious stroma fibrosis and inflammation

Mild response

Absence of or slight necrosis and degeneration of tumor cells accompanied by mild stroma fibrosis and inflammation

Becker-TRG

1a

No residual tumor/tumor bed

1b

<10% residual tumor/tumor bed

2

10–50% residual tumor/tumor bed

3

>50% residual tumor/tumor bed

Statistical analysis

Correlations between tumor regression evaluation systems and clinicopathological characteristics were performed by χ2 tests. And 2-sided p-values < 0.05 were considered statistically significant. The survival curve and median survival time were calculated using Kaplan-Meier method and log rank test. The univariate analysis of survival was evaluated by univariate Cox regression analysis. The statistic significant factors in univariate analysis were assessed by backward stepwise multivariate Cox regression analysis. Variables with a p-value of <0.05 were retained, and variables with a p-value of >0.10 were removed. All statistics were performed by SPSS 16.0 software (SPSS Inc, Chicago, IL).

Results

Clinicopathological characteristics

All the 192 patients received radical surgery. Forty-nine patients underwent proximal subtotal gastrectomy. Eighty-eight patients underwent distal subtotal gastrectomy. Fifty-three patients underwent total gastrectomy. Two patients underwent residual gastrectomy, both of which underwent distal gastrectomy previously due to severe ulcer. Sixty-three patients underwent D1 lymphadenectomy and 129 underwent D2 lymphadenectomy. The examined numbers of the removed lymph nodes per case ranged from 3 to 58. One-hundred and fifty-nine patients got R0 resection (82.8%). Twenty-one patients had local unresectable residues detected macroscopically by the surgeons while 12 had microscopically positive margins. Forty-four patients had adenocarcinoma of the esophagogastric junction (22.9%), 71 had tumors located at proximal stomach (37.0%), while 77 had tumors located at distal stomach (40.1%). We used maximal diameter of residual tumor/tumor bed to describe the size of tumor, which was divided into three groups [8]: <4.5 cm (n = 108, 56.3%), 4.5–8 cm (n = 64, 33.3%) and >8 cm (n = 20, 10.4%). The clinicopathological characteristics were tabulated in Tables 2, 3, 4, 5 and 6.
Table 2

Relationships between clinicopathological characteristics and pathological response evaluated by Mandard-TRG system

Characteristics

Total cases (n = 192), no. (%)

Mandard-TRG

P value

1 (n = 11), no. (%)

2 (n = 23), no. (%)

3 (n = 40), no. (%)

4 (n = 78), no. (%)

5 (n = 40), no. (%)

Gender

      

0.039

 Male

139 (72.4)

10 (7.2)

20 (14.4)

29 (20.9)

48 (34.5)

32 (23)

 

 Female

53 (27.6)

1 (1.9)

3 (5.7)

11 (20.8)

30 (56.6)

8 (15.1)

 

Age

      

0.867

 < 55y

89 (46.4)

6 (6.7)

10 (11.2)

17 (19.1)

39 (43.8)

17 (19.1)

 

 ≥ 55y

103 (53.6)

5 (4.9)

13 (12.6)

23 (22.3)

39 (37.9)

23 (22.3)

 

Location

      

0.351

 Esophagogastric junction

44 (22.9)

1 (2.3)

4 (9.1)

8 (18.2)

20 (45.5)

11 (25)

 

 Proximal gastric

71 (37)

7 (9.9)

8 (11.3)

15 (21.1)

23 (32.4)

18 (25.4)

 

 Distal gastric

77 (40.1)

3 (3.9)

11 (14.3)

17 (22.1)

35 (45.5)

11 (14.3)

 

Maximal diameter of tumor bed

      

0.004

 < 4.5 cm

108 (56.2)

9 (8.3)

20 (18.5)

20 (18.5)

44 (40.7)

15 (13.9)

 

 4.5–8 cm

64 (33.3)

1 (1.6)

3 (4.7)

17 (26.6)

27 (42.2)

16 (25)

 

 > 8 cm

20 (10.4)

1 (5)

0 (0)

3 (15)

7 (35)

9 (45)

 

Histological differentiation

      

0.003

 Well-moderate

45 (23.4)

4 (8.9)

12 (26.7)

9 (20)

16 (35.6)

4 (8.9)

 

 Poor

147 (76.6)

7 (4.8)

11 (7.5)

31 (21.1)

62 (42.2)

36 (24.5)

 

Laurén classification

      

0.240

 Intestinal

77 (40.1)

4 (5.2)

14 (18.2)

14 (19.2)

28 (36.4)

15 (19.5)

 

 Diffuse

73 (38)

7 (9.6)

5 (6.8)

10 (23.8)

33 (45.2)

14 (19.2)

 

 Mixed

42 (21.9)

0 (0)

4 (9.5)

15 (35.7)

17 (40.5)

11 (26.2)

 

LVI

      

<0.001

 Negative

94 (49)

11 (11.7)

19 (20.2)

28 (29.8)

26 (27.7)

10 (10.6)

 

 Positive

98 (51)

0 (0)

4 (4.1)

12 (12.2)

52 (53.1)

30 (30.6)

 

PNI

      

<0.001

 Negative

76 (39.6)

11 (14.5)

22 (28.9)

13 (17.1)

23 (30.3)

7 (9.2)

 

 Positive

116 (60.4)

0 (0)

1 (0.9)

27 (23.3)

55 (47.4)

33 (28.4)

 

AJCC ypT category

      

<0.001

 0

11 (5.7)

11 (100)

0 (0)

0 (0)

0 (0)

0 (0)

 

 1

20 (10.4)

0 (0)

12 (60)

5 (25)

3 (15)

0 (0)

 

 2

23 (12)

0 (0)

5 (21.7)

6 (26.1)

12 (52.2)

0 (0)

 

 3

57 (29.7)

0 (0)

5 (8.8)

18 (31.6)

25 (43.9)

9 (15.8)

 

 4

81 (42.2)

0 (0)

1 (1.2)

11 (13.6)

38 (46.9)

31 (38.3)

 

AJCC ypN category

      

<0.001

 0

55 (28.6)

9 (16.4)

13 (23.6)

17 (30.9)

10 (18.2)

6 (10.9)

 

 1

36 (18.8)

0 (0)

6 (16.7)

7 (19.4)

16 (44.4)

7 (19.4)

 

 2

50 (26)

0 (0)

3 (6)

10 (20)

32 (64)

5 (10)

 

 3

51 (26.6)

2 (3.9)

1 (2)

6 (11.8)

20 (39.2)

22 (43.1)

 

AJCC stage

      

<0.001

 0

9 (4.7)

9 (100)

0 (0)

0 (0)

0 (0)

0 (0)

 

 1

24 (12.5)

0 (0)

14 (58.3)

7 (29.2)

2 (8.3)

1 (4.2)

 

 2

53 (27.6)

2 (3.8)

6 (11.3)

14 (26.4)

21 (39.6)

10 (18.9)

 

 3

106 (55.2)

0 (0)

3 (2.8)

19 (17.9)

55 (51.9)

29 (27.4)

 

R0 resection

      

0.185

 Yes

159 (82.8)

11 (6.9)

20 (12.6)

35 (22)

64 (40.3)

29 (18.2)

 

 No

33 (17.2)

0 (0)

3 (9.1)

5 (15.2)

14 (42.4)

11 (33.3)

 

Adjuvant chemotherapy

      

0.766

 Not received

59 (30.7)

3 (5.1)

6 (10.2)

10 (16.9)

25 (42.4)

15 (25.4)

 

 Received

133 (69.3)

8 (6)

17 (12.8)

30 (22.6)

53 (39.8)

25 (18.8)

 
Table 3

Relationships between clinicopathological characteristics and pathological response evaluated by JGCA-TRG system

Characteristics

Total cases (n = 192), no. (%)

JGCA -TRG

P value

3 (n = 11), no. (%)

2 (n = 63), no. (%)

1b (n = 45), no. (%)

1a (n = 33), no. (%)

0 (n = 40), no. (%)

Gender

      

0.097

 Male

139 (72.4)

10 (7.2)

48 (34.5)

30 (21.6)

19 (13.7)

32 (23)

 

 Female

53 (27.6)

1 (1.9)

15 (28.3)

15 (28.3)

14 (26.4)

8 (15.1)

 

Age

      

0.711

 < 55y

89 (46.4)

6 (6.7)

26 (29.2)

24 (27)

16 (18)

17 (19.1)

 

 ≥ 55y

103 (53.6)

5 (4.9)

37 (35.9)

21 (20.4)

17 (16.5)

23 (22.3)

 

Location

      

0.287

 Esophagogastric junction

44 (22.9)

1 (2.3)

12 (27.3)

10 (22.7)

10 (22.7)

11 (25)

 

 Proximal gastric

71 (37)

7 (9.9)

23 (32.4)

15 (21.1)

8 (11.3)

18 (25.4)

 

 Distal gastric

77 (40.1)

3 (3.9)

28 (36.4)

20 (26)

15 (19.5)

11 (14.3)

 

Maximal diameter of tumor bed

      

<0.001

 < 4.5 cm

108 (56.2)

9 (8.3)

40 (37)

27 (25)

17 (15.7)

15 (13.9)

 

 4.5–8 cm

64 (33.3)

1 (1.6)

21 (32.8)

14 (21.9)

12 (18.8)

16 (25)

 

 > 8 cm

20 (10.4)

1 (5)

2 (10)

4 (20)

4 (20)

9 (45)

 

Histological differentiation

      

0.060

 Well-moderate

45 (23.4)

4 (8.9)

21 (46.7)

10 (22.2)

6 (13.3)

4 (8.9)

 

 Poor

147 (76.6)

7 (4.8)

42 (28.6)

35 (23.8)

27 (18.4)

36 (24.5)

 

Laurén classification

       

 Intestinal

77 (40.1)

4 (5.2)

29 (37.7)

18 (23.4)

11 (14.3)

15 (19.5)

 

 Diffuse

73 (38)

7 (9.6)

20 (27.4)

16 (21.9)

16 (21.9)

14 (19.2)

 

 Mixed

42 (21.9)

0 (0)

14 (33.3)

11 (26.2)

6 (14.3)

11 (26.2)

 

LVI

      

<0.001

 Negative

94 (49)

11 (11.7)

46 (48.9)

19 (20.2)

8 (8.5)

10 (10.6)

 

 Positive

98 (51)

0 (0)

17 (17.3)

26 (26.5)

25 (25.5)

30 (30.6)

 

PNI

      

<0.001

 Negative

76 (39.6)

11 (14.5)

35 (46.1)

14 (18.4)

9 (11.8)

7 (9.2)

 

 Positive

116 (60.4)

0 (0)

28 (24.1)

31 (26.7)

24 (20.7)

33 (28.4)

 

AJCC ypT category

      

<0.001

 0

11 (5.7)

11 (100)

0 (0)

0 (0)

0 (0)

0 (0)

 

 1

20 (10.4)

0 (0)

17 (85)

1 (5)

2 (10)

0 (0)

 

 2

23 (12)

0 (0)

11 (47.8)

6 (26.1)

6 (26.1)

0 (0)

 

 3

57 (29.7)

0 (0)

24 (42.1)

16 (28.1)

8 (14)

9 (15.8)

 

 4

81 (42.2)

0 (0)

11 (13.6)

22 (27.2)

17 (21)

31 (38.3)

 

AJCC ypN category

      

<0.001

 0

55 (28.6)

9 (16.4)

30 (54.5)

5 (9.1)

5 (9.1)

6 (10.9)

 

 1

36 (18.8)

0 (0)

13 (26)

11 (30.6)

5 (13.9)

7 (19.4)

 

 2

50 (26)

0 (0)

13 (26)

21 (42)

11 (22)

5 (10)

 

 3

51 (26.6)

2 (3.9)

7 (13.7)

8 (15.7)

12 (23.5)

22 (43.1)

 

AJCC stage

      

<0.001

 0

9 (4.7)

9 (100)

0 (0)

0 (0)

0 (0)

0 (0)

 

 1

24 (12.5)

0 (0)

21 (87.5)

1 (4.2)

1 (4.2)

1 (4.2)

 

 2

53 (27.6)

2 (3.8)

20 (37.7)

12 (22.6)

9 (17)

10 (18.9)

 

 3

106 (55.2)

0 (0)

22 (20.8)

32 (30.2)

23 (21.7)

29 (27.4)

 

R0 resection

      

0.046

 Yes

159 (82.8)

11 (6.9)

55 (34.6)

40 (25.2)

24 (15.1)

29 (18.2)

 

 No

33 (17.2)

0 (0)

8 (24.2)

5 (15.2)

9 (27.3)

11 (33.3)

 

Adjuvant chemotherapy

      

0.676

 Not received

59 (30.7)

3 (5.1)

16 (27.1)

13 (22)

12 (20.3)

15 (25.4)

 

 Received

133 (69.3)

8 (6)

47 (35.3)

32 (24.1)

21 (15.8)

25 (18.8)

 
Table 4

Relationships between clinicopathological characteristics and pathological response evaluated by CAP-TRG system

Characteristics

Total cases (n = 192), no. (%)

CAP-TRG

P value

0 (n = 11), no. (%)

1 (n = 23), no. (%)

2 (n = 40), no. (%)

3 (n = 118), no. (%)

Gender

     

0.134

 Male

139 (72.4)

10 (7.2)

20 (14.4)

29 (20.9)

80 (57.6)

 

 Female

53 (27.6)

1 (1.9)

3 (5.7)

11 (20.8)

38 (71.7)

 

Age

     

0.880

 < 55y

89 (46.4)

6 (6.7)

10 (11.2)

17 (19.1)

56 (62.9)

 

 ≥ 55y

103 (53.6)

5 (4.9)

13 (12.6)

23 (22.3)

62 (60.2)

 

Location

     

0.525

 Esophagogastric junction

44 (22.9)

1 (2.3)

4 (9.1)

8 (18.2)

31 (70.5)

 

 Proximal gastric

71 (37)

7 (9.9)

8 (11.3)

15 (21.1)

41 (57.7)

 

 Distal gastric

77 (40.1)

3 (3.9)

11 (14.3)

17 (22.1)

46 (59.7)

 

Maximal diameter of tumor bed

     

0.013

 < 4.5 cm

108 (56.2)

9 (8.3)

20 (18.5)

20 (18.5)

59 (54.6)

 

 4.5–8 cm

64 (33.3)

1 (1.6)

3 (4.7)

17 (26.6)

43 (67.2)

 

 > 8 cm

20 (10.4)

1 (5)

0 (0)

3 (15)

16 (80)

 

Histological differentiation

     

0.002

 Well-moderate

45 (23.4)

4 (8.9)

12 (26.7)

9 (20)

20 (44.4)

 

 Poor

147 (76.6)

7 (4.8)

11 (7.5)

31 (21.1)

98 (66.7)

 

Laurén classification

     

0.143

 Intestinal

77 (40.1)

4 (5.2)

14 (18.2)

14 (19.2)

47 (64.4)

 

 Diffuse

73 (38)

7 (9.6)

5 (6.8)

10 (23.8)

28 (66.7)

 

 Mixed

42 (21.9)

0 (0)

4 (9.5)

15 (35.7)

23 (54.8)

 

LVI

     

<0.001

 Negative

94 (49)

11 (11.7)

19 (20.2)

28 (29.8)

36 (38.3)

 

 Positive

98 (51)

0 (0)

4 (4.1)

12 (12.2)

82 (83.7)

 

PNI

     

<0.001

 Negative

76 (39.6)

11 (14.5)

22 (28.9)

13 (17.1)

30 (39.5)

 

 Positive

116 (60.4)

0 (0)

1 (0.9)

27 (23.3)

88 (75.9)

 

AJCC ypT category

     

<0.001

 0

11 (5.7)

11 (100)

0 (0)

0 (0)

0 (0)

 

 1

20 (10.4)

0 (0)

12 (60)

5 (25)

3 (15)

 

 2

23 (12)

0 (0)

5 (21.7)

6 (26.1)

12 (52.2)

 

 3

57 (29.7)

0 (0)

5 (8.8)

18 (31.6)

34 (59.6)

 

 4

81 (42.2)

0 (0)

1 (1.2)

11 (13.6)

69 (85.2)

 

AJCC ypN category

     

<0.001

 0

55 (28.6)

9 (16.4)

13 (23.6)

17 (30.9)

16 (29.1)

 

 1

36 (18.8)

0 (0)

6 (16.7)

7 (19.4)

23 (63.9)

 

 2

50 (26)

0 (0)

3 (6)

10 (20)

37 (74)

 

 3

51 (26.6)

2 (3.9)

1 (2)

6 (11.8)

42 (82.4)

 

AJCC stage

     

<0.001

 0

9 (4.7)

9 (100)

0 (0)

0 (0)

0 (0)

 

 1

24 (12.5)

0 (0)

14 (58.3)

7 (29.2)

3 (12.5)

 

 2

53 (27.6)

2 (3.8)

6 (11.3)

14 (26.4)

31 (58.5)

 

 3

106 (55.2)

0 (0)

3 (2.8)

19 (17.9)

84 (79.2)

 

R0 resection

     

0.212

 Yes

159 (82.8)

11 (6.9)

20 (12.6)

35 (22)

93 (58.5)

 

 No

33 (17.2)

0 (0)

3 (9.1)

5 (15.2)

25 (75.8)

 

Adjuvant chemotherapy

     

0.69

 Not received

59 (30.7)

3 (5.1)

6 (10.2)

10 (16.9)

40 (67.8)

 

 Received

133 (69.3)

8 (6)

17 (35.3)

30 (22.6)

78 (58.6)

 
Table 5

Relationships between clinicopathological characteristics and pathological response evaluated by China-TRG system

Characteristics

Total cases (n = 192), no. (%)

China-TRG

P value

Severe response (n = 34), no. (%)

Moderate response (n = 57), no. (%)

Mild response (n = 101), no. (%)

Gender

    

0.063

 Male

139 (72.4)

30 (21.6)

41 (29.5)

68 (48.9)

 

 Female

53 (27.6)

4 (7.5)

16 (30.2)

33 (62.3)

 

Age

    

0.820

 < 55y

89 (46.4)

15 (16.9)

25 (28.1)

49 (55.1)

 

 ≥ 55y

103 (53.6)

19 (18.4)

32 (31.1)

52 (50.5)

 

Location

    

0.906

 Esophagogastric junction

44 (22.9)

6 (13.6)

14 (31.8)

24 (54.5)

 

 Proximal gastric

71 (37)

14 (19.7)

22 (31)

35 (49.3)

 

 Distal gastric

77 (40.1)

14 (18.2)

21 (27.3)

42 (54.5)

 

Maximal diameter of tumor bed

    

<0.001

 < 4.5 cm

108 (56.2)

28 (25.9)

32 (29.6)

48 (44.4)

 

 4.5–8 cm

64 (33.3)

5 (7.8)

21 (32.8)

38 (59.4)

 

 > 8 cm

20 (10.4)

1 (5)

4 (20)

15 (75)

 

Histological differentiation

    

0.001

 Well-moderate

45 (23.4)

16 (35.6)

12 (26.7)

17 (37.8)

 

 Poor

147 (76.6)

18 (12.2)

45 (30.6)

84 (57.1)

 

Laurén classification

    

0.264

 Intestinal

77 (40.1)

18 (23.4)

22 (28.6)

37 (48.1)

 

 Diffuse

73 (38)

13 (17.8)

20 (27.4)

40 (54.8)

 

 Mixed

42 (21.9)

3 (7.1)

15 (35.7)

24 (57.1)

 

LVI

    

<0.001

 Negative

94 (49)

30 (31.9)

35 (37.2)

29 (30.9)

 

 Positive

98 (51)

4 (4.1)

22 (22.4)

72 (73.5)

 

PNI

    

<0.001

 Negative

76 (39.6)

33 (43.4)

20 (26.3)

23 (30.3)

 

 Positive

116 (60.4)

1 (0.9)

37 (31.9)

78 (67.2)

 

AJCC ypT category

    

<0.001

 0

11 (5.7)

11 (100)

0 (0)

0 (0)

 

 1

20 (10.4)

12 (60)

5 (25)

3 (15)

 

 2

23 (12)

5 (21.7)

8 (34.8)

10 (43.5)

 

 3

57 (29.7)

5 (8.8)

26 (45.6)

26 (45.6)

 

 4

81 (42.2)

1 (1.2)

18 (22.2)

62 (76.5)

 

AJCC ypN category

    

<0.001

 0

55 (28.6)

22 (40)

18 (32.7)

15 (27.3)

 

 1

36 (18.8)

5 (13.9)

12 (33.3)

19 (52.8)

 

 2

50 (26)

4 (13.9)

19 (38)

27 (54)

 

 3

51 (26.6)

3 (5.9)

8 (15.7)

40 (78.4)

 

AJCC stage

    

<0.001

 0

9 (4.7)

9 (100)

0 (0)

0 (0)

 

 1

24 (12.5)

14 (58.3)

7 (29.2)

3 (12.5)

 

 2

53 (27.6)

7 (13.2)

17 (32.1)

29 (54.7)

 

 3

106 (55.2)

4 (3.8)

33 (31.1)

69 (65.1)

 

R0 resection

    

0.1

 Yes

159 (82.8)

31 (19.5)

49 (30.8)

79 (49.7)

 

 No

33 (17.2)

3 (9.1)

7 (21.2)

23 (69.7)

 

Adjuvant chemotherapy

    

0.975

 Not received

59 (30.7)

10 (16.9)

17 (28.8)

32 (54.2)

 

 Received

133 (69.3)

24 (18)

39 (29.3)

70 (52.6)

 
Table 6

Relationships between clinicopathological characteristics and pathological response evaluated by Becker-TRG system

Characteristics

Total cases (n = 192), no. (%)

Becker-TRG

P value

1a (n = 11), no. (%)

1b (n = 23), no. (%)

2 (n = 67), no. (%)

3 (n = 91), no. (%)

Gender

     

0.142

 Male

139 (72.4)

10 (7.2)

20 (14.4)

45 (32.4)

64 (46)

 

 Female

53 (27.6)

1 (1.9)

3 (5.7)

22 (41.5)

27 (50.9)

 

Age

     

0.945

 < 55y

89 (46.4)

6 (6.7)

10 (11.2)

31 (34.8)

42 (47.2)

 

 ≥ 55y

103 (53.6)

5 (4.9)

13 (12.6)

36 (35)

49 (47.6)

 

Location

     

0.562

 Esophagogastric junction

44 (22.9)

1 (2.3)

4 (9.1)

15 (34.1)

24 (54.5)

 

 Proximal gastric

71 (37)

7 (9.9)

8 (11.3)

24 (33.8)

32 (45.1)

 

 Distal gastric

77 (40.1)

3 (3.9)

11 (14.3)

28 (36.4)

35 (45.5)

 

Maximal diameter of tumor bed

     

0.003

 < 4.5 cm

108 (56.2)

9 (8.3)

20 (18.5)

35 (32.4)

44 (40.7)

 

 4.5–8 cm

64 (33.3)

1 (1.6)

3 (4.7)

28 (43.8)

32 (50)

 

 > 8 cm

20 (10.4)

1 (5)

0 (0)

4 (20)

15 (75)

 

Histological differentiation

     

0.003

 Well-moderate

45 (23.4)

4 (8.9)

12 (26.7)

14 (31.1)

15 (33.3)

 

 Poor

147 (76.6)

7 (4.8)

11 (7.5)

53 (36.1)

76 (51.7)

 

Laurén classification

     

0.127

 Intestinal

77 (40.1)

4 (5.2)

14 (18.2)

25 (32.5)

34 (44.2)

 

 Diffuse

73 (38)

7 (9.6)

5 (6.8)

24 (32.9)

37 (50.7)

 

 Mixed

42 (21.9)

0 (0)

4 (9.5)

18 (42.9)

20 (47.6)

 

LVI

     

<0.001

 Negative

94 (49)

11 (11.7)

19 (20.2)

39 (41.5)

25 (26.6)

 

 Positive

98 (51)

0 (0)

4 (4.1)

28 (28.6)

66 (67.3)

 

PNI

     

<0.001

 Negative

76 (39.6)

11 (14.5)

22 (28.9)

22 (28.9)

21 (27.6)

 

 Positive

116 (60.4)

0 (0)

1 (0.9)

45 (38.8)

70 (60.3)

 

AJCC ypT category

     

<0.001

 0

11 (5.7)

11 (100)

0 (0)

0 (0)

0 (0)

 

 1

20 (10.4)

0 (0)

12 (60)

5 (25)

3 (15)

 

 2

23 (12)

0 (0)

5 (21.7)

10 (43.5)

8 (34.8)

 

 3

57 (29.7)

0 (0)

5 (8.8)

29 (50.9)

23 (40.4)

 

 4

81 (42.2)

0 (0)

1 (1.2)

23 (28.4)

57 (70.4)

 

AJCC ypN category

     

<0.001

 0

55 (28.6)

9 (16.4)

13 (23.6)

19 (34.5)

14 (25.5)

 

 1

36 (18.8)

0 (0)

6 (16.7)

16 (44.4)

14 (38.9)

 

 2

50 (26)

0 (0)

3 (6)

21 (42)

26 (52)

 

 3

51 (26.6)

2 (3.9)

1 (2)

11 (21.6)

37 (72.5)

 

AJCC stage

     

<0.001

 0

9 (4.7)

9 (100)

0 (0)

0 (0)

0 (0)

 

 1

24 (12.5)

0 (0)

14 (58.3)

7 (29.2)

3 (12.5)

 

 2

53 (27.6)

2 (3.8)

6 (11.3)

21 (39.6)

24 (45.3)

 

 3

106 (55.2)

0 (0)

3 (2.8)

39 (36.8)

64 (60.4)

 

R0 resection

     

0.234

 Yes

159 (82.8)

11 (6.9)

20 (12.6)

57 (35.8)

71 (44.7)

 

 No

33 (17.2)

0 (0)

3 (9.1)

10 (30.3)

20 (60.6)

 

Adjuvant chemotherapy

     

0.912

 Not received

59 (30.7)

3 (5.1)

6 (10.2)

20 (33.9)

30 (50.8)

 

 Received

133 (69.3)

8 (6)

17 (35.3)

47 (35.3)

61 (45.9)

 

Tumor regression assessment

We assessed 192 patients using the five TRG systems respectively. According to Mandard-TRG system, there were 11 patients in grade 1, 23 in grade 2, 40 in grade 3, 78 in grade 4, and 40 in grade 5. According to JGCA-TRG system, there were 11 patients in grade 3, 63 in grade 2, 45 in grade 1b, 33 in grade 1a, and 40 in grade 0. According to CAP-TRG system, there were 11 patients in grade 0, 23 patients in grade 1, 40 patients in grade 2, and 118 patients in grade 3. According to China-TRG system, there were 34 patients in severe response grade, 57 in moderate response grade, and 101 in mild response grade. According to Becker-TRG system, there were 11 patients in grade 1a, 23 patients in grade 1b, 67 patients in grade 2, and 91 patients in grade 3 (Tables 2, 3, 4, 5 and 6).

Correlation between tumor regression and clinicopathological features

Tumor regression evaluated by all the five grading systems has been found significantly associated with histological differentiation, postsurgical T category, postsurgical N category, AJCC stage, LVI, PNI and tumor size (P < 0.05) (Tables 2, 3, 4, 5 and 6).

Survival analysis

One hundred and eighty-one patients were analyzed in survival analysis. At the final follow-up, 81 patients (44.8%) were alive with no evidence of recurrence, while 16 (8.8%) were alive with recurrence. Eighty-three patients (45.9%) had died due to disease recurrence, while 1 (0.5%) had died of unknown reason excluding disease recurrence.

All of the five TRG systems, histological differentiation, postsurgical T category, postsurgical N category, AJCC stage, LVI, PNI, Laurén classification, R0 resection and tumor size were significant (P < 0.05) correlated with OS and PFS in univariate Cox regression analyses (Table 7). The overall and progression-free survival curves of five TRG systems were present in Figs. 1 and 2, respectively.
Table 7

Univariate Cox regression analyses

Characteristics

OS

PFS

HR

95% CI

P value

HR

95% CI

P value

Gender

 Male (reference)

1

  

1

  

 Female

1.179

0.740–1.876

0.488

1.309

0.859–1.994

0.211

Age

 < 55y (reference)

1

  

1

  

 ≥ 55y

1.120

0.903–1.390

0.303

0.856

0.577–1.270

0.441

Location

 Esophagogastric junction (reference)

1

  

1

  

 Proximal gastric

0.952

0.555–1.632

0.857

0.829

0.506–1.358

0.456

 Distal gastric

0.634

0.360–1.117

0.115

0.631

0.380–1.046

0.074

Maximal diameter of tumor bed

1.712

1.275–2.299

<0.001

1.709

1.304–2.239

<0.001

Histological differentiation

3.057

1.617–5.782

0.001

2.667

1.513–4.699

0.001

Laurén classification

 Intestinal (reference)

1

  

1

  

 Diffuse

2.228

1.339–3.709

0.002

1.896

1.199–2.999

0.006

 Mixed

2.206

1.216–4.003

0.009

1.911

1.113–3.280

0.019

LVI

3.318

2.089–5.270

<0.001

3.324

2.180–5.069

<0.001

PNI

2.878

1.750–4.733

<0.001

2.724

1.737–4.271

<0.001

AJCC ypT category

1.876

1.457–2.415

<0.001

1.739

1.396–2.168

<0.001

AJCC ypN category

1.946

1.572–2.408

<0.001

1.918

1.578–2.330

<0.001

AJCC stage

2.484

1.724–3.580

<0.001

2.270

1.650–3.122

<0.001

Mandard-TRG

 1 (reference)

1

  

1

  

 2

0.98

0.244–3.929

0.977

1.293

0.343–4.877

0.704

 3

1.956

0.568–6.730

0.287

2.143

0.631–7.283

0.222

 4

2.717

0.836–8.831

0.096

3.155

0.979–10.168

0.054

 5

3.682

1.094–12.394

0.035

4.570

1.380–15.132

0.013

JGCA-TRG

 3 (reference)

1

  

1

  

 2

1.531

0.457–5.126

0.49

1.782

0.539–5.892

0.344

 1b

2.626

0.781–8.831

0.119

2.621

0.786–8.738

0.117

 1a

2.875

0.836–9.884

0.094

4.022

1.199–13.491

0.024

 0

3.676

1.092–12.371

0.035

4.556

1.376–15.085

0.013

CAP-TRG

 0 (reference)

1

  

1

  

 1

0.979

0.244–3.927

0.977

1.292

0.343–4.873

0.705

 2

1.953

0.568–6.719

0.288

2.140

0.630–7.272

0.223

 3

2.996

0.937–9.586

0.064

3.558

1.119–11.311

0.032

China-TRG

 Severe response (reference)

1

  

1

  

 Moderate response

1.719

0.808–3.657

0.160

1.661

0.834–3.308

0.149

 Mild response

2.856

1.450–5.628

0.002

2.868

1.544–5.328

0.001

Becker-TRG

 1a (reference)

1

  

1

  

 1b

0.980

0.244–3.927

0.977

1.292

0.343–4.872

0.705

 2

2.216

0.673–7.294

0.190

2.295

0.702–7.502

0.169

 3

3.109

0.964–10.028

0.058

3.964

1.239–12.681

0.020

R0 resection

 Yes (reference)

1

  

1

  

 No

3.382

2.022–5.659

<0.001

3.656

2.315–5.774

<0.001

Adjuvant chemotherapy

 Not received (reference)

1

  

1

  

 Received

1.040

0.633–1.707

0.878

1.227

0.774–1.943

0.384

Fig. 1

Overall survival curves of five TRG systems, respectively. a Mandard-TRG, b JGCA-TRG, c CAP-TRG, d China-TRG and e Becker-TRG

Fig. 2

Progression-free survival curves of five TRG systems, respectively. a Mandard-TRG, b JGCA-TRG, c CAP-TRG, d China-TRG and e Becker-TRG

Postsurgical T category, postsurgical N category, R0 resection and LVI were independent predictors for OS, while LVI, postsurgical N category and R0 resection were independent predictors for PFS, revealed by backward multivariate Cox regression models (Table 8). None of the five tumor regression grading systems were found statistically significant in multivariate survival analysis. In Mandard-TRG system using univariate Cox analysis, the hazard ratio of no response grade was 3.682 and 4.57 in OS and PFS, respectively. In JGCA-TRG system using univariate Cox analysis, the hazard ratio of no response grade was 3.676 and 4.556 in OS and PFS, respectively (Table 7). In the Kaplan-Meier analysis, the median survival time of OS was 84.4 months for patients with Grade 2 in Mandard-TRG system, and 57.8 months for those with Grade 2 in JGCA-TRG system (Table 9).
Table 8

Multivariate Cox regression analyses

Characteristics

OS

PFS

HR

95% CI

P value

HR

95% CI

P value

Histological differentiation

-

-

-

1.662

0.914–3.022

0.096

LVI

1.651

0.976–2.793

0.062

1.766

1.091–2.861

0.021

AJCC ypT category

1.355

1.029–1.784

0.031

-

-

-

AJCC ypN category

1.487

1.168–1.894

0.001

1.479

1.180–1.855

<0.001

R0 resection

2.386

1.398–4.073

0.001

2.457

1.516–3.985

<0.001

Table 9

Comparison of median survival time between Mandard-TRG and JGCA-TRG

TRG systems

Median for survival time

OS

PFS

Mandard-TRG

 1

Not reached

Not reached

 2

84.4

Not reached

 3

51.8

42.4

 4

38.7

22.1

 5

24.3

12.8

JGCA-TRG

 3

Not reached

Not reached

 2

57.8

51.8

 1b

38.7

29.3

 1a

30.8

9.6

 0

24.3

12.8

Discussion

Neoadjuvant and adjuvant therapy have been applied to improve the outcome of localized advanced GC, especially in east Asia [11]. Preoperative therapy promoted R0 resection rates in some randomized studies [12]. Although the efficacy of preoperative chemotherapy could be partially reflected by the Response Evaluation Criteria in Solid Tumors (RECIST), RECIST is not always consistent with histopathological regression and prognosis. Thus the relationship among histopathological tumor regression evaluation, efficiency of the multimodality therapy and prognosis requires further illumination. Globally, there have been many kinds of histopathological tumor regression grading systems. Mandard et al. first published their five-tiered TRG system for esophageal carcinoma in 1994. It was reproducible and used widely in carcinomas of esophagus/esophagogastric junction and rectum, but there have been no published applications in GC yet. CAP recommended a simplified four-tiered TRG system based on Mandard-TRG system. In China, a three-tiered grading system is used to assess therapeutic response for solid malignancies. However, its applicability on GC remained unclear. Becker et al. proposed a semi-quantitative four-tiered TRG system in 2003, and then they proved the applicability on GC in 2011. In Japan, the wildly used method to evaluate pathological response is JGCA-TRG, of which the criteria for tumor regression separation are quite distinct from the other four TRG systems.

In this study, 118 (61.4%) patients had mild or minimal tumor regression. Only 11 (5.7%) cases got complete regression without any residual tumor cells on the primary sites, but unfortunately 2 of them were found with residual lymph nodes metastasis, probably resulting in poor outcomes. Twenty-three (12.0%) patients had nearly complete regression with a few residual tumor cells. We supposed the patients who reached complete response should have a better prognosis while the patients who reached nearly complete response should have a worse prognosis. However the actual results did not confirm this. Agoston et al. defined pathological complete response as neither residual primary tumor nor residual lymph node metastasis existing [13]. They reviewed esophageal adenocarcinoma 93 cases with complete response and found that adequacy of histological examination of the tumor bed affected the prognosis. In our study, the number of tumor blocks ranged from 4 to 53 in the complete response cases, while the number ranged from 5 to 77 in the nearly complete response cases. The fewer blocks of some cases might indicate potentially insufficient tumor sampling. Meanwhile, in some other studies which emphasized on adequacy of gross sampling, the percentage of complete response in GC ranged from 1.2 to 3.6% [1416]. Among the 23 nearly complete response cases in our study, only 5 were classified to postsurgical T3 or T4 categories, while the others were suspected to have earlier T categories before the preoperative therapy. This could be supposed to explain the different prognosis between patients who reached complete response and the patients who had nearly complete response. It is controversial on whether separating the complete response from the nearly complete response. Becker et al. separated the complete response category from the nearly complete response category and assessed separately, however, they combined them for survival analysis [9].

Chirieac et al. demonstrated their TRG system as an independent predictor on esophageal and esophagogastric junction cancer. They evaluated the residual tumor semi-quantitatively as 0% residue, 1–50% residue and >50% residue [17]. Becker et al. found the significance in multivariate analysis on the proportion of residual tumor between <10 and >10% in GC [9]. Both studies were based on large number of patients and long-term follow-up. On contrary, more studies did not demonstrate the independent role of TRG for prognosis. In our univariate survival analysis, all the five TRG systems showed statistical significance which was coincident with other studies [12, 14, 18, 19]. We collected exhaustive clinicopathological characteristics to establish the reliability of this study. The results indicated that all the TRG systems tightly correlated with LVI, postsurgical T and N categories, therefore the staging status and LVI would affect the statistical significance of the TRG systems in multivariate survival analysis. This could elucidate the absence of independent significance of the TRG systems. As compared with other grading systems, the hazard ratio of no/slightly response grade in both Mandard-TRG system and JGCA-TRG system revealed higher hazard of death and disease progression than that of severe response grade when using univariate Cox survival analysis. Furthermore, the main difference between the two five-tiered TRG systems is whether separating the category of nearly complete response from partial response. In Mandard-TRG system, the category of nearly complete response is separated, however, in JGCA-TRG system, it is not. Because the median survival time of patients with nearly complete response in Mandard-TRG system (84.4 months) was much longer than those with partial response in JGCA-TRG (57.8 months) (Table 9), separation of nearly complete response and partial response categories in Mandard-TRG system could be more reasonable for prognosis prediction.

Conclusions

This study analyzed five classic TRG systems on GC after neoadjuvant chemotherapy and revealed the significance of all the five TRG systems in univariate survival analysis. We recommend Mandard-TRG system in GC evaluation for prediction of survival.

Abbreviations

AJCC: 

American Joint Committee on Cancer

CAP: 

College of American Pathologists

GC: 

Gastric cancer

JGCA: 

The Japanese Gastric Cancer Association

LVI: 

Lymph-vascular invasion

OS: 

Overall-survival

PFS: 

Progression-free-survival

PNI: 

Perineural invasion

RECIST: 

Response Evaluation Criteria in Solid Tumors

TRG: 

Tumor regression grading

Declarations

Acknowledgements

We thank Lu Yu for providing advice on data presentation for this manuscript.

Funding

The design of the study and collection, analysis, and interpretation of data and in writing the manuscript was supported by National Natural Science Foundation of China (No. 81402463), and the Beijing Hope Run Special Fund (No. LC2013B34, No. LC2012B26 and LC2015A03) .

Availability of data and materials

The datasets during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

LX and LY designed this study. YS and YZ enrolled patients and collected clinical data. YZ, JY and LX evaluated pathological sections. LX, YJ, SH, XX and YZ conducted statistical analysis. The manuscript was drafted by YZ, YS, JY and reviewed for content by LX, XX, SH and YJ. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

This study was conducted after approval by the Independent Ethics Committee from National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (No. NCC2013RE-049). The consent was not required from each patient because this is a retrospective study. All procedures were performed in line with the declaration of Helsinki’s version of 1983.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Pathology and Resident Training Base, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
(2)
Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
(3)
Department of Cancer Epidemiology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
(4)
Department of Pathology, Esophageal Carcinoma Hospital of Linzhou

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.View ArticlePubMedGoogle Scholar
  2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.View ArticlePubMedGoogle Scholar
  3. Newton AD, Datta J, Loaiza-Bonilla A, Karakousis GC, Roses RE. Neoadjuvant therapy for gastric cancer: current evidence and future directions. J Gastrointest Oncol. 2015;6:534–43.PubMedPubMed CentralGoogle Scholar
  4. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73:2680–6.View ArticlePubMedGoogle Scholar
  5. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.
  6. Laura HT, Jordan B, Philip B, Lawrence JB, David KC, Carolyn CC, Patrick F, Wendy LF, John J, Sanjay K, Bruce M, Raouf N, Kay W. Protocol for the examination of specimens from patients with carcinoma of the stomach. In: CANCER PROTOCOL. College of American Pathologists. 2014. Http://www.cap.org/ShowProperty?nodePath=/UCMCon/Contribution%20Folders/WebContent/pdf/cp-stomach14-protocol.pdf. Accessed 11 June 2014.
  7. Ou GF, Wang M, Wang LH, Yin WB, Gu XZ. Relation between pathologic tumor response to preoperative radiotherapy and the prognosis in patients with esophageal carcinoma. Zhonghua zhong liu za zhi. 2003;25:278–81.PubMedGoogle Scholar
  8. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Bottcher K, Siewert JR, Hofler H. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521–30.View ArticlePubMedGoogle Scholar
  9. Becker K, Langer R, Reim D, Novotny A, Meyer zum Buschenfelde C, Engel J, Friess H, Hofler H. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg. 2011;253:934–9.View ArticlePubMedGoogle Scholar
  10. AJCC. PART III: digestive systems. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti III A, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. p. 103–26.Google Scholar
  11. Schirren R, Reim D, Novotny AR. Adjuvant and/or neoadjuvant therapy for gastric cancer? A perspective review. Ther Adv Med Oncol. 2015;7:39–48.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23:8688–96.View ArticlePubMedGoogle Scholar
  13. Agoston AT, Zheng Y, Bueno R, Lauwers GY, Odze RD, Srivastava A. Predictors of disease recurrence and survival in esophageal adenocarcinomas with complete response to neoadjuvant therapy. Am J Surg Pathol. 2015;39:1085–92.View ArticlePubMedGoogle Scholar
  14. Mansour JC, Tang L, Shah M, Bentrem D, Klimstra DS, Gonen M, Kelsen DP, Brennan MF, Coit DG. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann Surg Oncol. 2007;14:3412–8.View ArticlePubMedGoogle Scholar
  15. Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg. 1999;229:303–8.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Becker K, Reim D, Novotny A, Zum Buschenfelde CM, Engel J, Friess H, Hofler H, Langer R. Proposal for a multifactorial prognostic score that accurately classifies 3 groups of gastric carcinoma patients with different outcomes after neoadjuvant chemotherapy and surgery. Ann Surg. 2012;256:1002–7.View ArticlePubMedGoogle Scholar
  17. Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, Roth JA, Rashid A, Hamilton SR, Wu TT. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103:1347–55.View ArticlePubMedGoogle Scholar
  18. Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, Janjan N, Feig B, Faust J, Yao JC, Nivers R, Morris J, Pisters PW. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol. 2005;23:1237–44.View ArticlePubMedGoogle Scholar
  19. Rohatgi PR, Mansfield PF, Crane CH, Wu TT, Sunder PK, Ross WA, Morris JS, Pisters PW, Feig BW, Gunderson LL, Ajani JA. Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer. 2006;107:1475–82.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement